Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Hemispherx Biopharma Inc (NYSE MKT LLC:HEB)

0.177
Delayed Data
As of 11:00am ET
 -0.0018 / -1.01%
Today’s Change
0.14
Today|||52-Week Range
0.40
-29.20%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$44.1M

Company Description

Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.

Contact Information

Hemispherx Biopharma, Inc.
One Penn Center
Philadelphia Pennsylvania 19103
P:(215) 988-0080
Investor Relations:

Employees

Shareholders

Other institutional3.17%
Mutual fund holders2.70%
Individual stakeholders2.15%

Top Executives

William A. CarterChairman, CEO & Chief Science Officer
Wayne S. SpringateSenior Vice President-Operations
Thomas Kenwood EquelsVice Chairman, President, CFO & Secretary
David R. StrayerCMO, Medical Director & Head-Regulatory Affairs
Ralph Christopher CavalliVice President-Quality Control